Standard care plus every compound studied in the literature (each cited) and graded by evidence, organized by clinical readiness. A category, not a verdict that anything works — confirm anything here with your oncology team.
1
Interventions
0
Standard of care
0
Tested in people
1
Lab / animal
0
Named in lit.
1
Classes
1
Standard of care (0) Guideline option (0) Tested in people (0) Lab / animal only (1) Named in the literature (0)
"Tested in people" rows show the highest trial phase found in that compound's cited human studies (Phase I–IV; "phase not reported" = a human study with no phase tag). "Studied" = named in the cited literature for this cancer. "FDA ✓" = FDA-approved for this cancer; "off-label" = an FDA-approved drug used outside its approved indications (per openFDA). Not a claim that anything works.
Living document — last change June 9, 2026: New cancer type added.
Overview
Prostate Cancer is tracked here from the published studies that mention it. This page shows the research evidence collected so far — it is not a curated clinical overview.
What supports this page
The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.
Guideline
85
Meta-analysis
110
Systematic review
30
Randomized trial
2
Clinical trial
4
Observational
0
Case report
11
Review
515
Preclinical
0
Other
0
Evidence on specific compounds
How the published studies grade individual drugs, supplements, and other agents in Prostate Cancer — each rated by how strong the evidence is, not a recommendation.
What recent studies report in Prostate Cancer
These are reviewed studies whose abstracts concern Prostate Cancer. Each describes only what that study reported. This is not a claim by OncoForge that any compound helps or harms Prostate Cancer. Most are early lab, animal, or small human studies, and findings often conflict.
International journal of molecular sciences · Aug 2021 · review
breast cancercolon cancerprostate cancerendometrial cancerthyroid cancerbladder cancerglioblastomaadrenocortical carcinomaovarian epithelial carcinoma
This review discusses nucleobindin-2/nesfatin-1 (NUCB2/NESF-1) as a cancer-related molecule. It summarizes reports that higher expression is linked with poorer outcomes and with increased cancer cell proliferation, migration, and invasion in several cancers, while other reports suggest it may inhibit growth in some cancer cell types. The article does not present new experimental data.
Key findings
High NUCB2/NESF-1 expression has been associated with poor outcomes in several cancers.
Reported effects include increased cell proliferation, migration, and invasion in breast, colon, prostate, endometrial, thyroid, and bladder cancers, and glioblastoma.
The review also notes conflicting findings where nesfatin-1 inhibited proliferation in human adrenocortical carcinoma and ovarian epithelial carcinoma cells.
The authors propose NUCB2/NESF-1 as a prognostic and predictive marker in cancers.
Limitations: Review article; no original experimental or clinical data.; The abstract summarizes heterogeneous prior studies with conflicting findings.; No quantitative effect estimates are reported in the abstract.; No details on study quality, sample sizes, or methods of the cited studies are provided..
This is a review of a molecule reported to be associated with cancer progression and prognosis, not a primary intervention study.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
This review describes fuzuloparib, an oral PARP inhibitor, and its development leading to approval in China. The approval was for platinum-sensitive recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in patients with a germline BRCA mutation after second-line or later chemotherapy. The abstract also notes that phase II and III trials are ongoing in other solid cancers.
Key findings
Fuzuloparib is an orally active PARP inhibitor.
It has been approved in China for platinum-sensitive recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in patients with germline BRCA mutation after second-line or above chemotherapy.
Phase II and III trials are investigating it in other solid cancers.
Limitations: Review article; no original study data in the abstract.; No efficacy or safety results are reported in the abstract.; No comparator, sample size, or quantitative outcomes are provided..
This is a drug approval review focused on fuzuloparib's use in ovarian and related cancers, not an experimental efficacy study.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Compounds with reported-positive results in Prostate Cancer
Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.
Limitations: Review article; no original study data in the abstract.; No efficacy or safety results are reported in the abstract.; No comparator, sample size, or quantitative outcomes are provided..
Evidence at a glance: compounds studied in Prostate Cancer
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.